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http://dx.doi.org/10.1016/j.kjms.201Abstract Accurate prognostication in advanced cancer may facilitate better palliative care.
An objective marker may be more applicable and appropriate than a subjective evaluation by
physicians. The aim of this study was to evaluate liver function tests as useful prognostic fac-
tors for survival in patients with advanced cancer. We recruited advanced cancer patients from
January 2007 to December 2009. Data on age, sex, cancer diagnosis, site of metastases, clin-
ical symptoms, and performance status were collected at the time of admission to the pallia-
tive care unit. Analyzed laboratory data were obtained on the Day 1 of admission to the
palliative care unit. A total of 522 patients were enrolled; 322 (61.7%) of them were males.
The mean age was 60.6  13.2 years. Multiple logistic regression analysis adjusting for age
and sex demonstrated aspartate transaminase (AST) > 80 IU/L [odds ratio (OR) Z 2.01,
p Z 0.010] and alanine transaminase > 80 IU/L (OR Z 1.89, p Z 0.047) were independentlys have no conflicts of interest relevant to this article.
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Liver function tests and advanced cancers 147significant prognostic factors of death within 14 days. AST > 80 IU/L (OR Z 3.67, p Z 0.017)
and albumin < 3.0 g/dL (ORZ 1.98, pZ 0.048) were independently significant prognostic fac-
tors of death within 6 months. Liver function tests may be useful prognostic factors for patients
in the palliative care unit, in addition to being useful for patients with hepatobiliary cancer or
liver metastasis. These biochemical tests of liver function with cutoff values can easily be used
in palliative care.
Copyright ª 2013, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Care for increasing quality of life and symptom relief are
the priority in shorter life expectancy such as when survival
time is measured in days, whereas curative and therapeutic
procedures would be practicable in patients with longer
survival times such as months or years. Accurate prognos-
tication of metastatic cancer patients is important to pa-
tients themselves as well as to their families and clinical
providers. Patients and families can plan their limited sur-
vival days well [1,2], whereas clinicians can make appro-
priate medical decisions [3,4].
Although clinicians’ subjective predictions and clinical
symptoms can be helpful for prognostication, they tend to
be overly optimistic and possibly inaccurate [5]. Prior
literature indicated an accuracy of less than two-thirds for
the estimation rate of clinicians’ predictions [6]. There-
fore, more accurate prediction tools for prognostication are
warranted. Additionally, objective indicators will be more
useful and easily applicable for less experienced health
providers and for providing explanations to families.
Studies have indicated the use of some biological markers
to predict the survival of advanced cancer patients,
including white blood cell (WBC) count, lymphocytes, C-
reactive protein (CRP), lactate dehydrogenase (LDH), al-
bumin (Alb), serum sodium (Na), uric acid, and blood urea
nitrogen [7e12].
Research on the relationship between liver function
tests and survival, especially in advanced cancer patients,
is lacking. Some empirical findings aroused our interest to
clarify the association between liver function tests and
survival durations. Previous studies have investigated liver
function tests as indicators of poor prognosis in hepato-
cellular carcinoma (HCC) [13,14], but fewer studies re-
ported the association between liver function tests and
prognosis of other cancer types.
We conducted the study by recruiting patients with
advanced cancer and collecting data on cancer types, symp-
toms, and signs, and other serological variables including
blood routine and biochemical parameters including AST,
ALT,Alb,andprothrombin time(PT).Theaimof this studywas
to identify whether liver function tests would be convenient
andpracticable parameters as an objectivemarker to predict
the survival time of advanced cancer patients.
Materials and methods
This retrospective study recruited 522 advanced cancer pa-
tients who were admitted to a cancer palliative care unit in
Southern Taiwan between January 2007 and December 2009.Advanced cancer patients were suggested by specialists to
receivepalliativecare if curativecancer therapywasno longer
applicable. This study was approved by the Institutional Re-
view Board of Kaohsiung Medical University Hospital, and
medical records and chart reviews were provided by the
hospital. All enrolled patients underwent a blood examination
on admission. Patients with acute liver failure or fulminant
hepatitis thatmighthavebeen inducedbyprevious treatment,
such as chemotherapy, or by viral infection, were excluded.
Patients’ information including age, sex, primary cancer
diagnosis, and site of metastases (especially liver) were
collected at the time of admission to the palliative care
unit. We recorded clinical symptoms including pain,
edema, fatigue, tumor wound, cognitive impairment,
anorexia, dysphagia, sleep disturbance, ascites, and jaun-
dice. Pain severity was measured by a numeric rating scale
(range, 0e10). Survival time (in days) was calculated from
the day of admission to the day of death or leaving our
palliative care unit, after which we conducted telephonic
interviews for a duration of 6 months.
Laboratory data on WBC count, platelet count, CRP level,
hemoglobin level, serum aspartate transaminase (AST),
alanine transaminase (ALT), serum creatinine, serum
ammonia, serumNa,potassium(K), ionized calcium level (ion
Ca), serumAlb, and PTwith an international normalized ratio
(INR)wereobtainedon theDay1ofadmission to thepalliative
care unit. The cutoff values for normal and abnormal labo-
ratory data depended on our Kaohsiung Medical University
Hospital normal laboratory range, except that ALT > 80 IU/L
and AST > 80 IU/L were twice the normal range.
Statistical analyses were performed using SPSS version
19.0 for Windows (IBM Inc., Somers, NY, USA). The level of
statistical significance was 0.05. The median survival times
were estimated by the KaplaneMeier method and the sur-
vival comparison was based on the log-rank test. Multiple
logistic regressions were used to study outcomes of patients
(died within 2 weeks to 6 months) associated with the liver
function tests separately after adjusting covariates
(including age and sex). We divided the patients into three
groups (Patients without hepatobiliary cancer, Patients
without liver metastasis, and Patients with hepatobiliary
cancer and liver metastasis) and analyzed these groups
separately to realize roles of liver function test, especially
in advanced cancer patients without hepatobiliary
involvement.Results
Of the total patients studied, 84.9% with advanced cancer
survived longer than 14 days; however, only 8.2% of these
148 H.-J. Tsai et al.patients survived more than 6 months. Survival rates in 1
month, 2 months, 3 months, 4 months, and 5 months were,
respectively, 67.0%, 46.2%, 33.1%, 23.9%, and 15.3%. The
demographic characteristics of these patients are shown in
Table 1. The mean age was 60.6  13.2 years, with the most
common decade being the 50s (30.7%), followed by the 70s
or older (25.3%) and the 60s (23.8%). The number of male
patients was 322 (61.7%). The most common sites of cancer
were the head and neck (19.9%), followed by the gastro-
intestinal tract (19.2%), hepatobiliary system (16.5%), and
respiratory tract (15.7%), in a descending order. Of the
total patients, 144 (27.6%) had been diagnosed with liver
metastasis using medical images (abdomen sonography,
magnetic resonance imaging, and computed tomography).
Table 2 shows the serological variables used in univariate
analysis related to survival time. A significantly shorter
survival time was observed in the following condition:
AST > 80 IU/L (pZ 0.006), ALT > 80 IU/L (pZ 0.018), and
Alb < 3.0 g/dL (p < 0.023). However, no statistical signifi-
cance was observed in survival times between normal and
abnormal data of WBC count, platelet count, CRP level,
creatinine, Na, K, ammonia, and ion Ca.
Clinical symptoms occurring in these patients are shown
in Table 3. We found that most symptoms, including
cognitive impairment, fatigue, dysphagia, ascites, edema,
jaundice, pain, sleep disturbance, and tumor fungating
wound, were not associated with shorter survival times.
However, the rate of anorexia was significantly higher with
a shorter survival time (p Z 0.037).
Multiple logistic regression analyses were used to clarify
the odds ratio (OR) of liver function tests including AST,
ALT, ammonia, PT_INR, and Alb on outcome (death within 2Table 1 Demographic characteristics of recruited
advanced cancer patients (n Z 522).
Characteristics Total n (%)
Sex
Male 322 (61.7)
Female 200 (38.3)
Age (y)
<40 16 (3.1)
40e49 90 (17.2)
50e59 160 (30.7)
60e69 124 (23.8)
70 132 (25.3)
Primary cancer site
Head and neck 104 (19.9)
Gastrointestinal tract 100 (19.2)
Hepatobiliary system 86 (16.5)
Respiratory system 82 (15.7)
Breast 36 (6.9)
Reproductive system 30 (5.7)
Urologic system 22 (4.2)
Pancreas 22 (4.2)
Hematologic system 18 (3.4)
Others 22 (4.2)
Liver metastasis
Yes 144 (27.6)
No 378 (72.4)weeks to 6 months) with adjustment for age and sex. We
analyzed three groups including patients without hep-
atobiliary cancer, without liver metastasis, and with hep-
atobiliary involvement by the same method. The ORs [with
95% confidence interval (CI)] from multiple logistic regres-
sion analyses in those who died within 2 weeks are shown in
Table 4. When these variables were categorized as
dichotomous and adjusted for age and sex, AST > 80 IU/L
(OR Z 2.01, p Z 0.010) and ALT > 80 IU/L (OR Z 1.89,
p Z 0.047) were independently significant prognostic fac-
tors of death within 2 weeks. In patients without hep-
atobiliary cancer and in those without liver metastasis,
AST > 80 IU/L, ALT > 80 IU/L, ammonia > 80 mg/dL,
PT_INR > 1.2, and Alb < 3.0 g/L were not significantly
associated with the prognosis of death within 2 weeks.
However, if these patients had been followed-up for at
least 6 months by telephone, as Table 5 reveals,
AST > 80 IU/L (OR Z 4.66, p Z 0.04), Alb < 3.0 g/dL
(OR Z 2.37, p Z 0.03), and PT_INR > 1.2 (OR Z 3.38,
p Z 0.049) would significantly be associated with the
outcome of death within 6 months in patients without
hepatobiliary cancer.Discussion
The present study clarified that elevated liver function
tests may serve as useful prognostic factors of poor prog-
nosis in advanced cancer patients. A higher AST level that
was twice the upper limit of normal range (>80 IU/L) and
hypoalbuminemia (Alb < 3.0 g/dL) were identified as being
associated with the outcome of death within 6 months in
all patients except those with hepatobiliary cancer.
AST > 80 IU/L had a higher OR (5.65) of death within 6
months in patients with hepatobiliary involvement. How-
ever, elevations of AST and ALTwere significantly related to
the outcome of death within 2 weeks in all patients and in
those with hepatobiliary involvement, but not in those
without hepatobiliary involvement. The relationship be-
tween liver enzymes and prognosis has been discussed in
HCC and liver diseases [13e15]. Chen et al. [13] and
Changchien et al. [14] reported an ALT level two times
higher than the upper limit of normal range and a higher
AST/ALT ratio as significant prognostic factors of HCC pa-
tients to predict poor survival. However, these two studies
focused on the association between HCC and liver enzymes,
and not on all types of cancers. Our findings demonstrated
that elevated AST would be an independently useful prog-
nostic factor for the other cancer types. Proctor et al. [16]
suggested that elevated AST (40 IU/L) has a higher hazard
ratio of 1.71 for cancer-specific death in 5-year survivals,
which is independent of the tumor site. Another cohort
study in patients aged 75 years and more revealed an as-
sociation between abnormal AST and increased cancer
mortality (56% increase in the hazard ratio) [17]. However,
research focusing on the relationship between advanced
cancer patients and liver function tests was few. Our study
offered an insight into the theory that AST would be a sig-
nificant and valuable prognostic factor for the survival
duration of advanced cancer patients.
Our study found serum Alb to be also an important
prognostic factor of advanced cancer survival. Alb is
Table 2 Median survival time by serologic characteristics of study participants for following 6 months.
Characteristics Na (%) Death (%) Median (days) 95% CI p*
Survival time 522 479 (91.8) 49.5 22e117
WBC (103/mL)
10.0 207 (39.7) 185 (89.4) 62 50e74 0.065
>10.0 315 (60.3) 294 (93.3) 41 31e51
Platelets (103/mL)
150 112 (21.5) 105 (93.7) 46 18e74 0.482
>150 408 (78.5) 373 (91.4) 52 43e61
Hemoglobin (g/dL)
10.0 302 (57.9) 272 (90.1) 58 46e70 0.046
>10.0 220 (42.1) 207 (94.1) 39 28e50
CRP (mg/mL)
5.0 13 (2.8) 10 (76.9) 43 0e88 0.180
>5.0 459 (97.2) 424 (92.4) 49 40e58
AST (IU/L)
80 404 (77.4) 365 (90.3) 54 43e65 0.006
>80 118 (22.6) 114 (96.6) 38 15e61
ALT (IU/L)
80 452 (86.6) 411 (90.3) 54 44e64 0.018
>80 70 (13.4) 68 (97.1) 37 22e52
Creatinine (mg/dL)
1.5 413 (83.6) 380 (92.0) 50 40e60 0.651
>1.5 81 (16.4) 74 (91.4) 58 22e94
Na (mmol/L)
135 321 (63.1) 297 (92.5) 45 33e57 0.144
>135 188 (36.9) 169 (89.9) 57 44e70
K (mmol/L)
5.0 435 (85.0) 399 (91.7) 49 40e58 0.697
>5.0 77 (15.0) 70 (90.9) 68 40e96
Ammonia (mg/dL)
80 388 (74.3) 354 (91.2) 56 45e67 0.291
>80 134 (25.7) 125 (93.3) 40 33e47
Ion Ca (mg/dL)
5.5 320 (80.2) 290 (90.6) 55 43e67 0.467
>5.5 79 (19.8) 73 (92.4) 49 30e68
PT_INR
1.2 371 (71.1) 335 (90.3) 56 43e69 0.084
>1.2 151 (28.9) 144 (95.4) 41 33e49
Albumin (g/dL)
3.0 254 (48.7) 240 (94.5) 41 33e49 0.023
>3.0 268 (51.3) 239 (89.1) 60 46e74
*Values of p by log-rank test of the KaplaneMeier method.
ALT Z alanine transaminase; AST Z aspartate transaminase; CI Z confidence interval; CRP Z C-reactive protein;
PT_INR Z prothrombin time with an international normalized ratio; WBC Z white blood cell.
a Numbers may not add up due to missing data.
Liver function tests and advanced cancers 149produced by the liver and may represent liver synthetic
function [18]. Serum Alb levels were used widely to identify
malnutrition and systemic inflammation response [19]. We
noticed that advanced cancer patients are commonly
associated with hypoalbuminemia, which is related to
cachexia, edema, and organ function decline in clinical
practice. The literature demonstrated that mild hypo-
albuminemia (Alb < 3.5 g/dL) would increase mortality in
patients with advanced cancer [9,20]. Wyld et al. [21]
indicated moderate hypoalbuminemia (<3.0 g/dL) to be a
poor prognostic factor in patients with advanced breast
cancer. Lower serum Alb levels are common in advancedcancer patients, and a previous study indicated that these
may lead to higher mortality rates due to malnutrition and
inflammation [22]. Our results supported the literature and
recommended hypoalbuminemia (<3.0 g/dL) as a practi-
cable prognostic factor of shorter survival in advanced
cancer patients.
We found increased PT to be a prognostic factor of a
shorter survival time in advanced cancer patients. The
prognostic significance of abnormal PT in cancer patients
was inconsistent in previous researches, which did not focus
on advanced cancer patients [23,24]. Our study demon-
strated the probably significant prognostic importance of
Table 3 Median survival time by clinical characteristics of
study participants for following 6 months.
N (%) Death (%) Median (d) 95% CI p*
Survival
time
522 479 (91.8) 49.5 22e117
Cognitive impairment
Yes 66 (12.6) 59 (89.4) 49 19e79 0.625
No 456 (87.4) 420 (92.1) 49 40e58
Fatigue
Yes 516 (98.9) 474 (91.9) 50 41e59 0.643
No 6 (1.1) 5 (83.3) 34 5e64
Anorexia
Yes 422 (80.8) 389 (92.2) 45 35e55 0.037
No 100 (19.2) 90 (90.0) 65 39e91
Dysphagia
Yes 158 (30.3) 139 (88.0) 45 27e63 0.440
No 364 (69.7) 340 (93.4) 52 42e62
Ascites
Yes 74 (14.2) 69 (93.2) 35 19e51 0.210
No 448 (85.8) 410 (91.5) 54 44e64
Edema
Yes 144 (27.6) 129 (89.6) 40 19e61 0.921
No 378 (72.4) 350 (92.6) 52 42e62
Jaundice
Yes 56 (10.7) 54 (96.4) 36 21e51 0.057
No 466 (89.3) 425 (91.2) 54 44e64
Pain
0e4 393 (75.3) 360 (91.6) 45 35e55 0.670
5e6 53 (10.2) 49 (92.5) 69 45e93
7e10 76 (14.5) 70 (92.1) 50 29e71
Sleep disturbance
Yes 32 (6.1) 27 (84.4) 63 27e99 0.324
No 490 (93.9) 452 (92.2) 49 40e58
Tumor fungating wound
Yes 60 (11.5) 56 (93.3) 42 33e51 0.509
No 462 (88.5) 423 (91.6) 54 44e64
*Values of p and 95% CI by log-rank test of the KaplaneMeier
method.
CI Z confidence interval.
Table 4 Liver function of advanced cancer patients who die
adjustment for age and sex for each model.
All patients
(n Z 522)
Patients with
hepatobilia
cancer (n Z
OR (95% CI) OR (95% C
AST > 80 IU/L 2.01 (1.18e3.43)* 1.86 (0.93e3
ALT > 80 IU/L 1.89 (1.01e3.54)* 1.83 (0.85e3
Ammonia > 80 mg/dL 0.84 (0.48e1.49) 0.56 (0.24e1
Albumin < 3.0 g/dL 1.17 (0.72e1.91) 0.88 (0.50e1
PT_INR > 1.2 1.03 (0.61e1.75) 0.75 (0.37e1
*p < 0.05.
ALT Z alanine transaminase; AST Z aspartate transaminase; CI Z co
with an international normalized ratio.
150 H.-J. Tsai et al.prolonged PT in advanced cancer patients. Abnormal
coagulation function was found commonly in cancer pa-
tients due to clinical progression and tumor burden [24,25].
Prolonged PT may be related to liver synthetic dysfunction,
bleeding tendency, severe sepsis, and disseminated intra-
vascular coagulation, which are frequently combined with
advanced cancer and a shortened survival time. Although
the detailed mechanism of abnormal PT in advanced cancer
is unclear, our findings recognized the possible relationship
between prolonged PT and short survival in advanced can-
cer patients. Hyperammonemia usually occurs in liver dis-
eases, and hyperammonemia also results from renal
disease, gastrointestinal bleeding, and chemotherapy, [26].
Kumar et al. [27] indicated an association between hyper-
ammonemia and poor outcome in liver diseases. We hy-
pothesized a relation between ammonia and
prognostication in advanced cancer patients, but it was not
significant in our study. Further studies are needed to
better understand this aspect.
We suppose that many factors may influence liver
function in advanced cancer patients. Potential reasons of
liver function impairment in advanced cancer patients may
include the direct effect of tumor, liver metastasis,
chemotherapeutic drugs, and infection. The combination of
liver function impairment and cancer-related complication
may aggravate their progression and shorten survival time.
In addition, malnutrition in advanced cancer patients has
been a common cause of death, which may be related to
tumor progression or cancer treatment. Malnutrition may
also be associated with inflammation response and there-
fore may affect liver function greatly. Furthermore, previ-
ous studies suggested cytokines as mediators for cancer
cachexia [28], and cachexia may result in hypo-
albuminemia. Therefore, low Alb levels are thought to be
reasonably related to poor prognosis in advanced cancer
patients and even accelerate patients’ death.
Our findings indicate that anorexia may predict shorter
survival in advanced cancer patients. Anorexia is a common
symptom in patients with elevated liver enzymes. We sup-
pose that the association between anorexia and impaired
liver function may predict poor prognostication. The liter-
ature demonstrates that the metabolic activity in the liver
would increase in cancer, and it may stimulate the hepatic
receptors and lead to suppression of appetite [29].d within 2 weeks, using multiple logistic regressions with
out
ry
436)
Patients without
liver metastasis
(n Z 378)
Patients with hepatobiliary
cancer and liver metastasis
(n Z 28)
I) OR (95% CI) OR (95% CI)
.70) 1.74 (0.91e3.32) 2.60 (1.23e5.47)*
.96) 2.13 (0.97e4.65) 1.63 (0.71e3.78)
.28) 0.75 (0.37e1.52) 1.16 (0.55e2.44)
.54) 0.98 (0.55e1.74) 2.59 (1.10e6.10) *
.51) 1.32 (0.71e2.46) 2.87 (0.88e9.37)
nfidence interval; OR Z odds ratio; PT_INR Z prothrombin time
Table 5 Liver function of advanced cancer patients who died within 6 months, using multiple logistic regressions with
adjustment for age and sex for each model.
All patients(n Z 522) Patients without
hepatobiliary cancer
(n Z 436)
Patients without liver
metastasis (n Z 378)
Patients with hepatobiliary
cancer and liver metastasis
(n Z 28)
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
AST > 80 IU/L 3.67 (1.27e10.66)* 4.66 (1.06e20.49)* 2.74 (0.80e9.33) 5.65 (1.22e26.09)*
ALT > 80 IU/L 3.64 (0.85e15.50) 4.78 (0.63e36.06) 3.94 (0.52e29.83) 5.54 (0.69e44.3)
Ammonia > 80 mg/dL 1.35 (0.63e2.91) 1.37 (0.51e3.67) 1.72 (0.64e4.65) 1.13 (0.39e3.30)
Albumin < 3.0 g/dL 1.98 (1.01e3.88)* 2.37 (1.07e5.22)* 1.70 (0.77e3.77) 2.47 (0.81e7.49)
PT_INR > 1.2 2.20 (0.95e5.06) 3.38 (1.01e11.33)* 1.86 (0.69e5.00) 2.87 (0.88e9.37)
*p < 0.05.
Liver function tests and advanced cancers 151Moreover, organ failure may occur in cancer patients with
anorexia due to malnutrition, eventually leading to
increased mortality [30]._ENREF_28 Thus, our study pre-
dicted that anorexia might predict poor survival in
advanced cancer patients.
In our study, the number of patients who died within 2
weeks was less than those who died within 6 months. It may
result in significant findings due to more analyzed patients
and our result was compatible with the above possibility.
Our findings may demonstrate an association between liver
function tests and prognostication in advanced cancers, but
to understand the mechanism or causality further research
is needed. In addition, we investigated whether jaundice
was related to short survival in advanced cancer patients.
Although jaundice did not predict short survival in our
study, it was less objective than serum bilirubin levels.
Further research may be designed to analyze the associa-
tion between serum bilirubin levels and survival duration.
In conclusion, liver function tests may be noticeable
prognostic factors of survival time in advanced cancer pa-
tients, in addition to being useful for patients with hep-
atobiliary cancer or liver metastasis. Biochemical tests may
be more certain and objective. Our study revealed that two
times higher AST and ALT levels, prolonged PT, and hypo-
albuminemia are likely to be prognostic factors of poor
survival in advanced cancer patients. These parameters
provide new insights into the prognostication in advanced
cancer.Acknowledgments
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